Drake West

Drake is a Research Associate at Octant specializing in assay development, process/automation engineering, and high throughput screening.

Prior to Octant, Drake established a laboratory program and served as lab manager at Alibi Ale Works, Lake Tahoe. He also interned at the University of Colorado’s Anschutz Medical Campus, where he investigated different drugs candidates for difficult-to-treat melanomas. Drake received his B.S. in Biomedical Microbiology and Biology from the University of Wisconsin – La Crosse. There, he established four different research projects, including bioelectromagnetism via magnetotactic bacteria and acetaminophen metabolite toxicity in aquatic systems.

In his free time, Drake enjoys playing outside, writing music, and trying new things!


Mukherjee, N., Skees, J., Todd, K.J. et al. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis 11, 443 (2020).

View LeadershipView Board of DirectorsView Full TeamView Scientific Advisory Board